In the early days of the second Trump administration, what will happen to various government science agencies is not yet clear. Given the communications blackout imposed on agencies including the NIH ...

Multisyn Tech is a top custom software development company that provides high-performance digital solutions to its clients. The organization creates custom enterprise software development and ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid leukemia (AML), which is associated with an increased risk of relapse. The ...

In this week’s edition of InnovationRx, we look at Elon Musk’s attack on USAID, lawsuits challenging Trump's healthcare executive orders, a new non-opioid painkiller, a key vote for RFK Jr ...

Cystic fibrosis drug developer Sionna Therapeutics is eyeing a $135 million initial public offering. Radiopharmaceuticals biotech AdvanCell raised a $112 million Series C round. Nuvectis Pharma priced ...

AdvanCell has raised an oversubscribed US$112 million ($178.6 million) Series C round, enticing investors with its plan to produce cutting-edge nuclear medicines and novel cancer treatments.

Other companies are looking at lead-212 RLTs, meanwhile, including ARTBIO and POINT Biopharma/AdvanCell, but Orano Med is thought to be in the lead in the category. Sanofi's chief executive Paul ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has successfully completed an oversubscribed US$112 million Series C financing. This funding round ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment by a long stretch. That honor belonged to the whopping $410 million netted ...

Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has successfully passed a set of important preclinical safety tests ahead of the upcoming HERACLES clinical trial. The company said ...